Market Overview

Ohr Pharmaceutical Merger With Neubase Therapeutics Approved By Shareholders

Ohr Pharmaceutical Merger With Neubase Therapeutics Approved By Shareholders

Ohr Pharmaceutical (NASDAQ: OHRP) announced that all of its proposals relating to its proposed merger with Neubase Therapeutics were approved by Ohr's stockholders at a special meeting held today.

Upon closing of the transaction, the combined company will change its name to “NeuBase Therapeutics Inc” and the NASDAQ trading symbol will become “NBSE."

Ohr Pharmaceutical shares were trading up 27% at $4.70. The stock has a 52-week high of $6.20 and a 52-week low of $1.60.

Related Links:

Study: ViiV Healthcare's 2-Drug HIV Regimen As Effective As 3

Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio

Posted-In: Neubase TherapeuticsM&A News Movers Trading Ideas Best of Benzinga


Related Articles (OHRP)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Transenterix Spikes Higher After Equity Investment, AutoLap Asset Sale

Series Of Large Options Trades Suggests More Volatility For Micron